{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:50Z","timestamp":1793211110201,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zhongguancun Precision Medicine Foundation's \"New Life\" Charity Project","award":["GXZDH48"],"award-info":[{"award-number":["GXZDH48"]}]},{"name":"the CSCO-Hengrui Oncology Research Fund","award":["Y-HR2020QN-0175"],"award-info":[{"award-number":["Y-HR2020QN-0175"]}]},{"name":"the China Health & Medical Development Foundation","award":["chmdf2025-xrky04-09"],"award-info":[{"award-number":["chmdf2025-xrky04-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06882-9","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:10:20Z","timestamp":1770700220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Jiayi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"38","key":"6882_CR1","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","volume":"23","author":"SG Fisher","year":"2004","unstructured":"Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin\u2019s lymphoma. Oncogene 23(38):6524\u20136534. https:\/\/doi.org\/10.1038\/sj.onc.1207843","journal-title":"Oncogene"},{"issue":"1","key":"6882_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50(1):74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"issue":"4","key":"6882_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/PAP.0000000000000117","volume":"23","author":"P Korkolopoulou","year":"2016","unstructured":"Korkolopoulou P, Vassilakopoulos T, Milionis V et al (2016) Recent advances in aggressive large B-cell lymphomas: a comprehensive review. Adv Anat Pathol 23(4):202\u2013243. https:\/\/doi.org\/10.1097\/PAP.0000000000000117","journal-title":"Adv Anat Pathol"},{"issue":"20","key":"6882_CR4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA et al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood 135(20):1759\u20131771. https:\/\/doi.org\/10.1182\/blood.2019003535","journal-title":"Blood"},{"key":"6882_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, Novo M, Paruzzo L et al (2022) Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev 110:102443. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102443","journal-title":"Cancer Treat Rev"},{"issue":"6769","key":"6882_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"issue":"4","key":"6882_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4):551-568.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"issue":"2","key":"6882_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1042\/BST20150261","volume":"44","author":"L Aschauer","year":"2016","unstructured":"Aschauer L, Muller PA (2016) Novel targets and interaction partners of mutant p53 gain-of-function. Biochem Soc Trans 44(2):460\u2013466. https:\/\/doi.org\/10.1042\/BST20150261","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"6882_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137(3):413\u2013431. https:\/\/doi.org\/10.1016\/j.cell.2009.04.037","journal-title":"Cell"},{"issue":"17","key":"6882_CR10","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","volume":"24","author":"SL Harris","year":"2005","unstructured":"Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24(17):2899\u20132908. https:\/\/doi.org\/10.1038\/sj.onc.1208615","journal-title":"Oncogene"},{"issue":"7","key":"6882_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41684-022-00998-x","volume":"51","author":"D Giannuzzi","year":"2022","unstructured":"Giannuzzi D, Marconato L, Fanelli A et al (2022) The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. Lab Anim 51(7):191\u2013202. https:\/\/doi.org\/10.1038\/s41684-022-00998-x","journal-title":"Lab Anim"},{"issue":"19","key":"6882_CR12","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C et al (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 120(19):3986\u20133996. https:\/\/doi.org\/10.1182\/blood-2012-05-433334","journal-title":"Blood"},{"issue":"9","key":"6882_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G et al (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43(9):830\u2013837. https:\/\/doi.org\/10.1038\/ng.892","journal-title":"Nat Genet"},{"issue":"12","key":"6882_CR14","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00277-023-05420-1","volume":"102","author":"OAEH Ebid","year":"2023","unstructured":"Ebid OAEH, Ezz El Arab LR, Saad AS, Ezz El Din M et al (2023) Prognostic impact of MYD88 and TP53 mutations in diffuse large B cell lymphoma. Ann Hematol 102(12):3477\u20133488. https:\/\/doi.org\/10.1007\/s00277-023-05420-1","journal-title":"Ann Hematol"},{"issue":"5","key":"6882_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","volume":"107","author":"A Dodero","year":"2022","unstructured":"Dodero A, Guidetti A, Marino F et al (2022) Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica 107(5):1153\u20131162. https:\/\/doi.org\/10.3324\/haematol.2021.278638","journal-title":"Haematologica"},{"issue":"28","key":"6882_CR16","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.18632\/oncotarget.24656","volume":"9","author":"A Dobashi","year":"2018","unstructured":"Dobashi A, Togashi Y, Tanaka N et al (2018) TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis. Oncotarget 9(28):19555\u201319568. https:\/\/doi.org\/10.18632\/oncotarget.24656","journal-title":"Oncotarget"},{"issue":"6","key":"6882_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW (2017) Putting p53 in context. Cell 170(6):1062\u20131078. https:\/\/doi.org\/10.1016\/j.cell.2017.08.028","journal-title":"Cell"},{"issue":"1","key":"6882_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy K, Lane DP (2018) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol 15(1):13\u201330. https:\/\/doi.org\/10.1038\/nrclinonc.2017.151","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"6882_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrc3711","volume":"14","author":"KT Bieging","year":"2014","unstructured":"Bieging KT, Mello SS, Attardi LD (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14(5):359\u2013370. https:\/\/doi.org\/10.1038\/nrc3711","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"6882_CR20","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124(24):4622\u20134632. https:\/\/doi.org\/10.1002\/cncr.31646","journal-title":"Cancer"},{"issue":"24","key":"6882_CR21","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1073\/pnas.1200019109","volume":"109","author":"K Edlund","year":"2012","unstructured":"Edlund K, Larsson O, Ameur A et al (2012) Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 109(24):9551\u20139556. https:\/\/doi.org\/10.1073\/pnas.1200019109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6882_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622\u2013629. https:\/\/doi.org\/10.1002\/humu.20495","journal-title":"Hum Mutat"},{"issue":"27","key":"6882_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"8","key":"6882_CR24","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","volume":"112","author":"KH Young","year":"2008","unstructured":"Young KH, Leroy K, M\u00f8ller MB et al (2008) Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112(8):3088\u20133098. https:\/\/doi.org\/10.1182\/blood-2008-01-129783","journal-title":"Blood"},{"issue":"1","key":"6882_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01765-w","volume":"22","author":"KX Du","year":"2024","unstructured":"Du KX, Wu YF, Hua W et al (2024) Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms. Cell Commun Signal 22(1):401. https:\/\/doi.org\/10.1186\/s12964-024-01765-w","journal-title":"Cell Commun Signal"},{"issue":"9","key":"6882_CR26","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","volume":"36","author":"Y Hong","year":"2022","unstructured":"Hong Y, Ren T, Wang X et al (2022) APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia 36(9):2269\u20132280. https:\/\/doi.org\/10.1038\/s41375-022-01634-w","journal-title":"Leukemia"},{"issue":"2","key":"6882_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.onc.1202314","volume":"18","author":"G Blandino","year":"1999","unstructured":"Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2):477\u2013485. https:\/\/doi.org\/10.1038\/sj.onc.1202314","journal-title":"Oncogene"},{"issue":"4","key":"6882_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s43018-023-00532-z","volume":"4","author":"Z Su","year":"2023","unstructured":"Su Z, Kon N, Yi J et al (2023) Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism. Nat Cancer 4(4):564\u2013581. https:\/\/doi.org\/10.1038\/s43018-023-00532-z","journal-title":"Nat Cancer"},{"issue":"10","key":"6882_CR29","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.immuni.2024.08.015","volume":"57","author":"Z Nian","year":"2024","unstructured":"Nian Z, Dou Y, Shen Y et al (2024) Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity 57(10):2344\u20132361e7. https:\/\/doi.org\/10.1016\/j.immuni.2024.08.015","journal-title":"Immunity"},{"issue":"48","key":"6882_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409764","volume":"11","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Sun J, Xu W et al (2024) MGAT4A\/Galectin9-Driven N-Glycosylation Aberration as a Promoting Mechanism for Poor Prognosis of Endometrial Cancer with TP53 Mutation. Adv Sci 11(48):e2409764. https:\/\/doi.org\/10.1002\/advs.202409764","journal-title":"Adv Sci"},{"key":"6882_CR31","doi-asserted-by":"publisher","unstructured":"Zhang LL, An L, Qi XL et al (2024) The prognostic predictive value of TP53 mutation variant allele frequency in diffuse large B-Cell lymphoma Zhongguo Shi Yan Xue ye Xue Za Zhi. 32(6):1719\u20131725. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2024.06.013","DOI":"10.19746\/j.cnki.issn.1009-2137.2024.06.013"},{"issue":"21","key":"6882_CR32","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","volume":"7","author":"AS Zayac","year":"2023","unstructured":"Zayac AS, Landsburg DJ, Hughes ME et al (2023) High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv 7(21):6381\u20136394. https:\/\/doi.org\/10.1182\/bloodadvances.2023009731","journal-title":"Blood Adv"},{"issue":"1","key":"6882_CR33","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1182\/blood-2023-177563","volume":"142","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Zhou JW, Shang M, Zhu Z, Zhu M (2023) Orelabrutinib plus R-CHOP regimen in treatment-na\u00efve patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL). Blood 142(1):6289. https:\/\/doi.org\/10.1182\/blood-2023-177563","journal-title":"Blood"},{"issue":"1","key":"6882_CR34","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1182\/blood-2025-1906","volume":"146","author":"Q Cai","year":"2025","unstructured":"Cai Q et al (2025) Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): a single-arm, phase II trial. Blood 146(1):1906\u20131906. https:\/\/doi.org\/10.1182\/blood-2025-1906","journal-title":"Blood"},{"issue":"12","key":"6882_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96(12):1679\u20131705. https:\/\/doi.org\/10.1002\/ajh.26367","journal-title":"Am J Hematol"},{"issue":"4","key":"6882_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"35","key":"6882_CR37","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO-25-00925","volume":"43","author":"F Morschhauser","year":"2025","unstructured":"Morschhauser F, Salles G, Sehn LH et al (2025) Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol 43(35):3698\u20133705. https:\/\/doi.org\/10.1200\/JCO-25-00925","journal-title":"J Clin Oncol"},{"issue":"1","key":"6882_CR38","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1002\/hon.70017","volume":"43","author":"P Zhao","year":"2025","unstructured":"Zhao P, Zhao S, Huang C et al (2025) Efficacy and safety of polatuzumab Vedotin plus Rituximab, Cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-Cell lymphoma: A Real-World, Multi-Center, retrospective cohort study. Hematol Oncol 43(1):e70017","journal-title":"Hematol Oncol"},{"issue":"1","key":"6882_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH (2024) Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 14(1):27. https:\/\/doi.org\/10.1038\/s41408-024-00997-w","journal-title":"Blood Cancer J"},{"issue":"42","key":"6882_CR40","doi-asserted-by":"publisher","first-page":"73168","DOI":"10.18632\/oncotarget.17324","volume":"8","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Wang H, Jin S et al (2017) Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients. Oncotarget 8(42):73168\u201373176. https:\/\/doi.org\/10.18632\/oncotarget.17324","journal-title":"Oncotarget"},{"issue":"4","key":"6882_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA et al (2022) Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J Clin Oncol 40(4):369\u2013381. https:\/\/doi.org\/10.1200\/JCO.21.02143","journal-title":"J Clin Oncol"},{"issue":"22","key":"6882_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225592","volume":"13","author":"E Porpaczy","year":"2021","unstructured":"Porpaczy E, Wohlfarth P, K\u00f6nigsbr\u00fcgge O et al (2021) Influence of TP53 mutation on survival of diffuse large B-cell lymphoma in the CAR T-cell era. Cancers (Basel) 13(22):5592. https:\/\/doi.org\/10.3390\/cancers13225592","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6882_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00924-0","volume":"7","author":"J Wei","year":"2022","unstructured":"Wei J, Xiao M, Mao Z et al (2022) Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther 7(1):101. https:\/\/doi.org\/10.1038\/s41392-022-00924-0","journal-title":"Signal Transduct Target Ther"},{"key":"6882_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241306236","volume":"13","author":"Z Cai","year":"2025","unstructured":"Cai Z, Zou D, Ma Q, Sun W, Guo Y (2025) Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed\/refractory diffuse large B-cell lymphoma with TP53 mutation: a case report. SAGE Open Med Case Rep 13:2050313X241306236. https:\/\/doi.org\/10.1177\/2050313X241306236","journal-title":"SAGE Open Med Case Rep"},{"issue":"15","key":"6882_CR45","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1182\/bloodadvances.2020001727","volume":"4","author":"L Meriranta","year":"2020","unstructured":"Meriranta L, Pasanen A, Alkodsi A et al (2020) Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv 4(15):3742\u20133753. https:\/\/doi.org\/10.1182\/bloodadvances.2020001727","journal-title":"Blood Adv"},{"key":"6882_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1550207","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin Y, Wang Y, Wang L et al (2025) TP53 mutation and immunohistochemical p53 expression characteristics in diffuse large B-cell lymphoma. Front Oncol 15:1550207. https:\/\/doi.org\/10.3389\/fonc.2025.1550207","journal-title":"Front Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06882-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:27Z","timestamp":1771949007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06882-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6882"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06882-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8231260\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Cancer Hospital of Shandong First Medical University (Approval No. SDTHEC2024006130) and Shengli Oilfield Central Hospital (Approval No. YXLL202504501). Given the retrospective design of the study and the use of archived specimens, the ethics committee waived the requirement for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}